BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15552412)

  • 1. Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer.
    Carlson DJ; Stewart RD; Li XA; Jennings K; Wang JZ; Guerrero M
    Phys Med Biol; 2004 Oct; 49(19):4477-91. PubMed ID: 15552412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How low is the alpha/beta ratio for prostate cancer?
    Wang JZ; Guerrero M; Li XA
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro determination of radiation sensitivity parameters for DU-145 prostate cancer cells.
    Wang JZ; Rhee JG; Shi P; Stewart RD; Allen Li X
    Int J Radiat Biol; 2008 Jun; 84(6):515-22. PubMed ID: 18470750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters.
    Carlson DJ; Stewart RD; Semenenko VA
    Med Phys; 2006 Sep; 33(9):3105-15. PubMed ID: 17022202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?
    Wang JZ; Li XA; Yu CX; DiBiase SJ
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
    Elgqvist J; Timmermand OV; Larsson E; Strand SE
    Anticancer Res; 2016 Jan; 36(1):103-9. PubMed ID: 26722033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
    Pop LA; Millar WT; Visser AG; van der Kogel AJ
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of heterogeneity in radiosensitivity on LQ based isoeffect formalism for low alpha/beta cancers.
    Moiseenko V
    Acta Oncol; 2004; 43(5):499-502. PubMed ID: 15360056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT).
    Wang JZ; Li XA; D'Souza WD; Stewart RD
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):543-52. PubMed ID: 12957268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose fractionation effects in primary and metastatic human uveal melanoma cell lines.
    van den Aardweg GJ; Kiliç E; de Klein A; Luyten GP
    Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4660-4. PubMed ID: 14578382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo.
    Leith JT; Quaranto L; Padfield G; Michelson S; Hercbergs A
    Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):283-7. PubMed ID: 8420876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is alpha/beta for prostate tumors really low?
    Fowler J; Chappell R; Ritter M
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1021-31. PubMed ID: 11429230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning.
    Guerrero M; Li XA
    Phys Med Biol; 2003 Oct; 48(20):3307-26. PubMed ID: 14620060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
    Xiong W; Li J; Ma CM
    Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What hypofractionated protocols should be tested for prostate cancer?
    Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCP isoeffect analysis using a heterogeneous distribution of radiosensitivity.
    Carlone M; Wilkins D; Nyiri B; Raaphorst P
    Med Phys; 2004 May; 31(5):1176-82. PubMed ID: 15191307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate.
    Sminia P; Schneider CJ; Fowler JF
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.
    Nahum AE; Movsas B; Horwitz EM; Stobbe CC; Chapman JD
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):391-401. PubMed ID: 12957250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line.
    Leith JT
    Prostate; 1994; 24(3):119-24. PubMed ID: 8115277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
    King CR; DiPetrillo TA; Wazer DE
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.